Exactech Announces Full Market Release of the Equinoxe® Shoulder Fracture Plate
GAINESVILLE, Fla. – April 28, 2011 -- Exactech, Inc. (Nasdaq: EXAC), a developer and
producer of bone and joint restoration products for hip, knee, shoulder, spine
and biologic materials, announced today that it is fully launching the Equinoxe® Fx Plate, the latest addition to Exactech’s
fast-growing Equinoxe® Platform Shoulder System.
Kenneth Egol, MD, professor and vice chair at NYU Hospital for Joint Diseases in New York City and chief of the division of Orthopaedic Trauma said that surgeons are reporting excellent early results through the use of this innovative new plate design. “The design team of surgeons and Exactech engineers worked diligently to identify clinical shortcomings common to complex shoulder fractures. We then collaborated to design an implant that addresses those clinical challenges. We’re excited about the fracture plate’s potential to reduce humeral head collapse following a traumatic injury to the shoulder. It also allows surgeons to deploy bone void filler after the plate is seated, which we have shown to minimize head collapse and thus improve outcomes in clinical practice.”
The fracture plate offers surgeons multiple screw/blade configurations and robust instrumentation to treat a broad spectrum of proximal humerus fractures with a wide array of surgical technique preferences. The contoured design allows suture placement after the plate is secured.
“From a strategic perspective, offering surgeons the ability to call one sales representative to provide the full array of solutions for a clinical challenge is differentiating and adds meaningful value,” said Darin Johnson, Exactech’s marketing director, extremities. “In the case of proximal humerus fractures, surgeons must sometimes decide intra-operatively whether to repair it with a plate and screws, or reconstruct with a hemi-arthroplasty or a reverse shoulder. The Equinoxe shoulder system now has great solutions for each of the options, and we offer that to the surgeon with one phone call to one sales representative.”
Gary Miller, PhD, Exactech’s executive vice president of research and development said, “We expect that innovative new products like this will continue to fuel the momentum that has enabled Equinoxe to become the fastest growing shoulder system in the U.S. We are gratified by the excellent outcomes and the response from our surgeon customers.”
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com/. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.
An investment profile on Exactech may be found at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.
Chief Financial Officer
352-377-1140 begin_of_the_skype_highlighting 352-377-1140 end_of_the_skype_highlighting
Julie Marshall or Frank Hawkins
305-451-1888 begin_of_the_skype_highlighting 305-451-1888 end_of_the_skype_highlighting